SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects

por Achiron, Anat, Gurevich, Michael, Falb, Rina, Dreyer-Alster, Sapir, Sonis, Polina, Mandel, Mathilda
Publicado 2021

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents

por Gurevich, Michael, Zilkha‐Falb, Rina, Sonis, Polina, Magalashvili, David, Dolev, Mark, Mandel, Mathilda, Menascu, Shay, Achiron, Anat
Publicado 2022

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients

por Gurevich, Michael, Zilkha-Falb, Rina, Sonis, Polina, Magalashvili, David, Menascu, Shay, Flechter, Shlomo, Dolev, Mark, Mandel, Mathilda, Achiron, Anat
Publicado 2022

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Flechter, Shlomo, Falb, Rina, Gurevich, Michael
Publicado 2021

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Flechter, Shlomo, Falb, Rina, Gurevich, Michael
Publicado 2021

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

por Achiron, Anat, Mandel, Mathilda, Gurevich, Michael, Dreyer-Alster, Sapir, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Harari, Gil, Flechter, Shlomo, Falb, Rina
Publicado 2022

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Magalashvili, David, Menascu, Shay, Warszawer, Yehuda, Dolev, Mark, Didikin, Maria, Harari, Gil, Sonis, Polina, Falb, Rina, Gurevich, Michael
Publicado 2023

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Dolev, Mark, Menascu, Shay, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Sonis, Polina, Zilkha-Falb, Rina, Gurevich, Michael
Publicado 2021

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

por Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Publicado 2022

Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis

por Levi, Izhak, Gurevich, Michael, Perlman, Gal, Magalashvili, David, Menascu, Shay, Bar, Noam, Godneva, Anastasia, Zahavi, Liron, Chermon, Danyel, Kosower, Noa, Wolf, Bat Chen, Malka, Gal, Lotan-Pompan, Maya, Weinberger, Adina, Yirmiya, Erez, Rothschild, Daphna, Leviatan, Sigal, Tsur, Avishag, Didkin, Maria, Dreyer, Sapir, Eizikovitz, Hen, Titngi, Yamit, Mayost, Sue, Sonis, Polina, Dolev, Mark, Stern, Yael, Achiron, Anat, Segal, Eran
Publicado 2021